Redoxis Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Employees
  • 24

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $905K

  • Investors
  • 4

Redoxis General Information

Description

Operator of pre-clinical research facilities intended to offer preclinical research, immunology, and in vivo studies. The company's platform focuses on preclinical drug development and efficacy evaluation in models of inflammatory and autoimmune diseases with strong roots in academic research, enabling healthcare professionals with tools for the investigation of therapeutic efficacy and mode of action of novel therapies.

Contact Information

Website
www.redoxis.se
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Scheelevägen 2
  • Medicon Village
  • 223 81 Lund
  • Sweden
+46 070-725
Primary Industry
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • Scheelevägen 2
  • Medicon Village
  • 223 81 Lund
  • Sweden
+46 070-725

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Redoxis Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Grant 11-Jan-2022 $905K Completed Generating Revenue
3. Grant 10-Sep-2019 Completed Generating Revenue
2. Early Stage VC (Series A) 30-Jun-2008 Completed Generating Revenue
1. Accelerator/Incubator Completed Startup
To view Redoxis’s complete valuation and funding history, request access »

Redoxis Patents

Redoxis Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2008330225-A1 New treatment of autoimmune conditions Inactive 28-Nov-2007
CA-2706849-A1 New treatment of autoimmune conditions Inactive 28-Nov-2007
EP-2212701-A1 New treatment of autoimmune conditions Inactive 28-Nov-2007
EP-2212701-A4 New treatment of autoimmune conditions Inactive 28-Nov-2007
US-20110200993-A1 New treatment of autoimmune conditions Inactive 28-Nov-2007 G01N33/5035
To view Redoxis’s complete patent history, request access »

Redoxis Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Redoxis Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
EUREKA Eurostars Government
European Commission Government
Sätila Impact Investment Impact Investing Minority
SmiLe Incubator Accelerator/Incubator Minority
To view Redoxis’s complete investors history, request access »

Redoxis Acquisitions (1)

Redoxis’s most recent deal was a Merger/Acquisition with ProNoxis. The deal was made on 26-Nov-2012.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
ProNoxis 26-Nov-2012 Merger/Acquisition Drug Discovery
To view Redoxis’s complete acquisitions history, request access »

Redoxis FAQs

  • When was Redoxis founded?

    Redoxis was founded in 2007.

  • Where is Redoxis headquartered?

    Redoxis is headquartered in Lund, Sweden.

  • What is the size of Redoxis?

    Redoxis has 24 total employees.

  • What industry is Redoxis in?

    Redoxis’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Redoxis a private or public company?

    Redoxis is a Private company.

  • What is Redoxis’s current revenue?

    The current revenue for Redoxis is .

  • Who are Redoxis’s investors?

    EUREKA Eurostars, European Commission, Sätila Impact Investment, and SmiLe Incubator have invested in Redoxis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process